Belfast-based Neurovalens closes £6m funding round
Belfast-based neurotechnology company Neurovalens has closed a £6 million (€6.95 million) investment round to help fund its commercial expansion in the US and global markets.
The funding round was led by Investment Fund for Northern Ireland, and includes participation from Whiterock’s Growth Capital Fund and follow-on support from existing investors IQ Capital, Innovation Ulster and the Angel Co-Fund, as well as private investors. It also includes a £1 million loan from the IFNI debt fund managed by Whiterock.
The money will be used to boost sales of its current medical devices, and seek additional approvals from US authorities.
